Table 2.
Univariate analysis of outcome by therapy and CD20 status in de novo precursor B cell ALL: pre-rituximab era
| Parameter | CD20 negative (N = 133) | P* | CD20 positive (N = 120) | P* | P** |
|---|---|---|---|---|---|
| No. (%) CR | |||||
| All | 111 (84) | 107 (89) | NS | ||
| VAD/CVAD | 38 of 56 (68) | < .001 | 45 of 54 (83) | .06 | .06 |
| Hyper-CVAD | 73 of 77 (95) | 62 of 66 (94) | NS | ||
| No. (%) relapse | |||||
| All | 47 of 111 (42) | 70 of 107 (65) | |||
| VAD/CVAD | 20 of 38 (53) | .01 | 32 of 45 (71) | .02 | .08 |
| Hyper-CVAD | 27 of 73 (37) | .01 | 38 of 62 (61) | .005 | |
| Percent 3-year remission duration | |||||
| All | 55 | 20 | < .001 | ||
| VAD/CVAD | 42 | 0.04 | 18 | NS | NS |
| Hyper-CVAD | 58 | 22 | < .001 | ||
| Percent 3-year overall survival | |||||
| All | 40 | 27 | .03 | ||
| VAD/CVAD | 28 | < .001 | 26 | NS | NS |
| Hyper-CVAD | 60 | 27 | .003 |
CR, complete remission; VAD, vincristine, Adriamycin, dexamethasone; CVAD, cyclophosphamide, VAD; hyper-CVAD, hyper-fractionated cyclophosphamide, vincristine, Adriamycin, dexamethasone.
*
P values represent significance levels of comparison of VAD/CVAD vs hyper-CVAD with CD20 subsets.
**
P values in final column represent significance levels of comparison of CD20 negative versus CD positive with each subset.